Latest tumour Stories
Hormone therapy has serious side effects and is therefore used only when the tumour has grown too large to be treated in any other way, or when the tumour has spread and formed metastases.
FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been approved...
Montreal, February 11th, 2009 - The development of cancerous tumours is highly dependent on the nutrients the tumours receive through the blood.
Researcher Kristina Djanashvili has developed a substance that enables doctors to get better MRI scans of tumours. On Tuesday 13 January, Djanashvili will be awarded a doctorate by TU Delft for her work in this field.
NERVIANO, Italy, October 23 /PRNewswire/ -- - First Responses in Solid Tumours Reported. Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour.
Many breast cancers are made worse by the hormone oestrogen and women take drugs known as aromatase inhibitors to reduce the oestrogen in their body and restrict the cancer's progress.
GENEVA, Sept. 1 /PRNewswire/ -- Chrigu from Switzerland has been awarded the Grand Prize in the first ever Reel Lives: Cancer Chronicles Film Festival at a ceremony in Geneva, Switzerland.
By Chotel, F Unnithan, A; Chandrasekar, C R; Parot, R; Jeys, L; Grimer, R J We have analysed the pattern of symptoms in patients presenting with synovial sarcoma to identify factors which led to long delays in diagnosis.
By PALMER, Rebecca ITS name is an unfamiliar mouthful and it is not one of "big cancers". But glioblastoma multiforme is the most common and aggressive primary brain tumour -- and there's no cure.
London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.